Suggested remit: To appraise the clinical and cost effectiveness of nusinersen and risdiplam within their marketing authorisations for treating spinal muscular atrophy. Anticipate the topic will be of ...

Around 200 people with chronic lymphocytic leukaemia (CLL) whose disease has returned after treatment are set to benefit from a new treatment option. Our draft guidance recommends pirtobrutinib (also ...

Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal) TA1144 8 April 2026 8 April 2026 Digital technologies ...

A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.

This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to ...

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It ...

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based ...

This guideline has been updated and replaced by NICE guideline CG137 ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441] ...

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] ...